3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Sarcoma
10
Sarcoma, Alveolar Soft Part
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Melanoma
2
Head and Neck Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Vulvar Neoplasms
1
Urogenital Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Clear Cell
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pancreatic Neoplasms
1
Obesity
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Interventions
Imatinib Mesylate
71
Sunitinib
31
regorafenib
17
nilotinib
15
ripretinib
13
avapritinib
7
Laparoscopy
5
Ipilimumab
5
Dasatinib
5
spartalizumab
4
CTLA-4 Antigen
4
Blood Specimen Collection
4
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4
pexidartinib
3
pazopanib
3
binimetinib
3
Temozolomide
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Paclitaxel
3
Oxaliplatin
3
Observation
3
Nivolumab
3
Midazolam
3
Leucovorin
3
Gemcitabine
3
Biopsy
3
Bevacizumab
3
trametinib
2
tanespimycin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
atezolizumab
×
Sarcoma
×
Clear all
NCT05152472
2026-04-24
ATEZOGIST
Centre Leon Berard
Phase 2
Recruiting
110 enrolled